RESUMO
Background and Aim: Bovine viral diarrhea virus (BVDV) and classical swine fever virus (CSFV) are important pathogens of cattle and pigs, respectively, and belong to the genus Pestivirus. As CSFV has been shown to infect cattle, it can create diagnostic challenges of BVDV results through possible cross-reactivity where cattle could be exposed to pigs and CSFV. This study aimed to determine the possible cross-reactivity of BVDV and CSFV enzyme-linked immunosorbent assay (ELISA) results for antigen (Ag) and antibody (Ab) among smallholder dairy cattle in Kenya. Materials and Methods: This was a cross-sectional study based on a single visit to farms to collect serum samples and other descriptive farm-level and animal-level information. Testing for BVDV Ag and Ab was conducted on serum samples from 320 dairy cows and heifers, with CSFV Ag and Ab testing conducted on a subset of 133 and 74 serum samples, respectively. CSFV testing was based on BVDV test results and the availability of enough sample volume from farms that kept pigs. The Ag and Ab tests utilized IDEXX ELISA for both BVDV and CSFV. Results: For the 74 samples with Ab tests for both viruses, 40 (54.0%) were BVDV Ab positive, while 63 (85.1%) were CSFV Ab positive. Of the 40 BVDV Ab positive samples, 36 cattle (90.0%) tested positive for CSFV Ab. However, of the 34 BVDV Ab negative samples, 27 (79.4%) were CSFV Ab test-positive. For the 133 samples with Ag tests for both viruses, 125 (94.0%) were BVDV Ag positive, while 2 (1.5%) samples were CSFV Ag positive. None of the eight BVDV Ag negative samples was positive for CSFV Ag and only two (1.6%) of the 125 BVDV Ag positive samples were positive for CSFV Ag. Conclusion: The results indicate either substantial cross-reactivity of the two Ab ELISA tests, or reactivity with some other protein in the samples that led to the positive Ab test results. There was only limited evidence for cross-reactivity of the two Ag ELISA tests. We recommend that Pestivirus genus cross-reactivity be considered when interpreting BVDV ELISA results in cattle, more for Ab than Ag tests. Further research is needed to clarify the levels of cross-reactivity between BVDV and other Pestivirus Ag and Ab tests from animals on mixed-species farms.
RESUMO
The aim of the study was to determine the antibody sero-prevalence of Bovine Herpesvirus-1 which cause Infectious Bovine Rhinotracheitis (IBR) and to identify risk factors associated with BHV-1 antibody seropositivity among smallholder dairy farms in Meru County, Kenya. A cross-sectional study was conducted in the Naari area of Meru County, Kenya between September-October 2016 and March-April 2017. The 149 farmers were randomly selected from members of the Naari Dairy Farmers Cooperative Society who were actively delivering milk to the society at the time of the study. Serum samples were obtained from 403 female dairy cattle. Farm level management and animal factors were collected through direct interviews with the owner or someone who was knowledgeable about the animals. All serum samples were processed with an indirect enzyme-linked immunosorbent assay (gB ELISA) to determine the presence of antibodies to BHV-1. The overall farm-level and animal-level sero-prevalences of BHV-1 antibodies were 30.9 % (95 % CI: 23.6%-39.0%) and 17.4 % (95 % CI: 13.8%-21.4%), respectively. In the final multivariable analysis, the factors significantly associated with BHV-1 antibodies included; age of the dairy cattle (ORâ¯=â¯1.200, pâ¯=â¯0.001), age of the principal female farmers (ORâ¯=â¯0.182, pâ¯=â¯0.001) and rearing goats in the farm (ORâ¯=â¯26.77, pâ¯=â¯0.000). There was a significant interaction between rearing goats on the farm and age of the dairy cattle (pâ¯<â¯0.010); younger cattle seemed to have been exposed to BHV or a cross-reacting caprine herpesvirus when goats were on the farm. The results showed that BHV-1 was circulating among the cattle population in the Naari area of Meru County. Given that there is not BHV-1 vaccination use in this study population, training on the importance of biosecurity and vaccination for BHV-1 are recommended to reduce the transmission and impacts of BHV-1.
